Navigation Links
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
Date:3/19/2013

NEW YORK, March 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Financial Assessment of the Global Pharmaceutical and Biotechnology Industry 
http://www.reportlinker.com/p01120885/Financial-Assessment-of-the-Global-Pharmaceutical-and-Biotechnology-Industry .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Financial Management is the Key Strategy for Sustainability

This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.

The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include:

•The global economic slowdown
•Regulatory compliance
•Reducing profitability
•Increasing R&D costs
•Pricing pressures
•Counterfeit business

Financial Analysis of the Pharmaceutical and Biotechnology Industry

1. Margin Analysis
•The pharmaceutical industry has generally witnessed smaller margins due to increasing competition from generics, pricing pressures, and decreasing healthcare spending.
•In the biotechnology industry, companies within low revenue range and relatively new products have witnessed negative margins because of the heavy investment in R&D and SG&A (selling and general expenses).

2. Profitability Analysis
•Companies with a large portfolio of drugs have seen higher profitability in the pharmaceutical industry.
•The long timelines and accumulating expenditures incurred before a drug is commercialized is making the biotechnology industry less profitable in initial years, even resulting in negative margins for companies that are smaller in terms of revenue.

3. Turnover Analysis
•In both the pharmaceutical and biotechnology industries, companies with lower revenue had poor turnover ratios because of the huge investments made in assets and in the development of the product.

4. Cash Reserve Analysis
•In the pharmaceutical industry the smaller companies in terms of revenue are increasing their cash reserve as a percentage of their assets.
•In the biotechnology industry, both small and large companies in terms of revenue are increasing their cash reserve as a percentage of their assets.

5. R&D to Sales Ratio
•Both the pharmaceutical and biotechnology industries did not witness a great variation in the R&D to sales ratio in 2011 compared to the previous year. Though there was a general decline in the overall sales in both the pharmaceutical and biotechnology industries, the R&D expenses were not considerably reduced.

Who Will Benefit?

•Pharmaceutical & biotechnology companies
•Private equity
•Venture capital investors
•Fund managers
•Retail investors
•Sovereign wealth funds
•Hedge funds
•Insurance funds and other members of the investing community

Table Of Contents

1. Executive Summary

2. Definition of Key Terms

3. Research Objective and Scope

4. Research Methodology

5. Key Issues/Challenges Faced by Industry Participants

6. Pharmaceutical Industry

7. Top Performers in the Pharmaceutical Industry

8. Biotechnology Industry

9. Top Performers in the Biotechnology Industry

10. The Frost & Sullivan Story

To order this report:
Pharmaceutical Industry: Financial Assessment of the Global Pharmaceutical and Biotechnology Industry 

__________________________
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
2. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
3. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
4. Organovo Reports 2012 Financial Results
5. Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
6. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
7. China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012
8. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
9. Discovery Labs Reports Fourth Quarter 2012 Financial Results
10. GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2012
11. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Walgreens has committed to provide drug disposal kiosks ... D.C. as part of a program to combat ... advocacy organization As You Sow. Conrad MacKerron , ... on to unneeded drugs because they lack easily accessible collection ... --> Conrad MacKerron , Senior Vice President at As ...
(Date:2/11/2016)... 11, 2016   Health 2.0 , the premiere ... technologies, announced today " 10 Year Global Retrospective ", ... over the past ten years.   ... Health 2.0 has served as the preeminent thought-leader in ... thousands of technologies, companies, innovators, and patient-activists through an ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent ... cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. Sadati ... procedures. One of the most common procedures he performs is his natural facelift. ...
(Date:2/11/2016)... Chicago, IL (PRWEB) , ... February 11, 2016 ... ... dedicated to the healthcare industry, ranked among the top five firms in the ... Services and HIT Implementation Support and Staffing. KLAS is a research and insights ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing curves. It’s ... older, who gather once a year to play softball to raise money through ... the more than 50 players who competed in this year’s softball tournament share a ...
(Date:2/11/2016)... Laredo, TX (PRWEB) , ... February 11, 2016 ... ... and surrounding communities with their ongoing community involvement program, introduces a new charity ... with hospitalized children, donations are now being accepted at https://donate.rmhc.org/ . , ...
Breaking Medicine News(10 mins):